AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2020
Apr 9, 2020
32134_dirs_2020-04-08_5dda25b2-52cf-442e-9008-aeb54f9af762.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2020-03-31
Reporting Person: Wilson Mark Andrew (SVP & General Counsel)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 53947 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $8.80 | 2021-02-05 | Common Stock (5344) | Direct | |
| Stock Option | $16.31 | 2022-12-08 | Common Stock (37500) | Direct | |
| Stock Option | $15.55 | 2023-12-14 | Common Stock (15000) | Direct | |
| Stock Option | $15.45 | 2024-07-14 | Common Stock (10000) | Direct | |
| Stock Option | $12.24 | 2024-12-12 | Common Stock (20000) | Direct | |
| Stock Option | $56.90 | 2025-12-14 | Common Stock (110000) | Direct | |
| Stock Option | $56.90 | 2025-12-14 | Common Stock (42000) | Direct | |
| Stock Option | $36.51 | 2026-12-13 | Common Stock (10225) | Direct | |
| Stock Option | $21.79 | 2027-12-11 | Common Stock (35800) | Direct | |
| Stock Option | $21.79 | 2027-12-11 | Common Stock (11600) | Direct |
Footnotes
F1: This number includes 31,574 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. This number also includes 2,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).
F2: As of March 31, 2020, 9,166 shares subject to this stock option are vested and exercisable. The remaining 834 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until July 15, 2020 based on continued service.
F3: As of March 31, 2020, 16,250 shares subject to this stock option are vested and exercisable. The remaining 3,750 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 13, 2020 based on continued service.
F4: As of March 31, 2020, 61,875 shares subject to this stock option are vested and exercisable. The remaining 48,125 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 15, 2021 based on continued service.
F5: As of March 31, 2020, 23,625 shares subject to this stock option are vested and exercisable. The remaining 18,375 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 15, 2021 based on continued service.
F6: As of March 31, 2020, 3,195 shares subject to this stock option are vested and exercisable. The remaining 7,030 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 14, 2022 based on continued service.
F7: As of March 31, 2020, 2,237 shares subject to this stock option are vested and exercisable. The remaining 33,563 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 12, 2023 based on continued service.
F8: As of March 31, 2020, 725 shares subject to this stock option are vested and exercisable. The remaining 10,875 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments until December 12, 2023 based on continued service.